



## **ten23 health is successfully ISO 9001:2015 certified**

**Basel, 11<sup>th</sup> of September 2023. ten23 health®, a global contract development and manufacturing organization, today announced the successful implementation and certification of the ISO 9001:2015 Quality Management for its Development services in Basel. This achievement underscores our unwavering commitment to delivering exceptional quality in the analytical and pharmaceutical development of sterile products.**

ISO 9001:2015 is a globally recognized standard that sets out the criteria for a quality management system, focusing on enhancing customer satisfaction through the effective application of the system, including processes for continual improvement and assurance of conformity to customer, normative, and regulatory requirements. Using ISO 9001 helps ensure that customers get consistent, good-quality products and services.

The newly implemented Quality Management System and certification according to ISO 9001:2015 requirements, encompasses every facet of our analytical and pharmaceutical development processes for sterile dosage forms at our BASE site in Basel. This includes development activities such as formulation development, analytical method development, primary packaging development, particle testing, container closure integrity (CCI) testing and the manufacture and testing of stability samples.

*“We are extremely proud to have achieved ISO 9001:2015 certification for our Development Services,”* said Hanns-Christian Mahler, CEO/Chief Enablement Officer of ten23 health. *“This milestone reflects the diligence and dedication of our entire team in consistently delivering products and services that ensure Service and data quality and hence exceed the expectations of our clients and partners.”*

The certification serves as an affirmation of our commitment to quality, transparency, reliability, traceability and continuous improvement. By adhering to ISO 9001:2015

standards, we aim to ensure and enhance operational efficiency, ensure quality of services and hence customer satisfaction. This achievement not only strengthens our position as a reliable partner in pharmaceutical development but also underscores our determination to uphold the highest industry standards. Our BASE<sup>®</sup> facility was previously implementing an electronic lab notebook system (eLN) for its Development Services, being a significant part of our quality standards.

Our team's expertise, combined with the rigor of our QMS, positions us to pioneer innovative solutions that drive positive impacts across the pharmaceutical landscape.

At ten23 health<sup>®</sup>, we take immense pride in being a human-centric and sustainable strategic partner of choice for both the pharmaceutical industry and biotech start-ups. Our comprehensive service offerings encompass the entire spectrum of pharmaceutical product development and testing. From the initial stages of pharmaceutical product design, through the meticulous manufacturing process, to critical QC testing and stability assessments, we are committed to ensuring the highest standards of quality and safety. With our unwavering dedication to innovation and excellence, ten23 health<sup>®</sup> stands at the forefront of tomorrow's medicines, shaping the future of healthcare.

### **About ten23 health<sup>®</sup>**

ten23 health<sup>®</sup>, located in Basel and Visp, Switzerland, is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups: we develop, manufacture, and test modern medicines. At our two sites in Basel and Visp, Switzerland, we support our clients in developing, manufacturing and testing differentiated, stable, usable, and safe injectable treatment options for patients.

ten23 health<sup>®</sup> combines the latest scientific findings with proven and tested world-class industry and regulatory expertise to forge new paths for supporting clients. We provide our innovative services in a fair and sustainable manner, respecting people's health and the future of our planet. ten23 health is solidly financed through the long-term commitment of 3i Group, an internationally reputable equity partner.

### **About BASE® and VIVA®**

BASE® and VIVA® are our two facilities in Basel and Visp Valais, Switzerland. It stands for our roots in Basel and life and nature in Valais. We have a strong connection to the local region, and we value our roots, life and nature and provide Swiss Quality. At ten23 health we embrace diversity with employees from different nationalities while still cherishing traditions. We are proud to be an employer in Switzerland where we can show our commitment to Patients, People and Planet.

### **About the company's name**

The numeric value for the number of molecules in a sample of one mol is called Avogadro constant and equals  $6.022 \cdot 10^{23}$ . Gram quantities of material contain the incredible number of  $10^{23}$  atoms, which was an important discovery to understand the composition of matter: The world is built from small units, and not a homogeneous mass.

### **About 3i Group**

3i is an investment company with two complementary businesses, Private Equity and Infrastructure, specializing in core investment markets in Northern Europe and North America. 3i's Private Equity team provides investment solutions for growing companies, backing entrepreneurs and management teams of mid-market companies with an Enterprise Value typically between €100m - €500m. The company backs international growth plans, providing access to its network and expertise to accelerate the growth of companies across the consumer, industrial, healthcare and business and technology services industries.

### **Media contacts:**

**ten23 health:** Mara Willa, [mara.willa@ten23.health](mailto:mara.willa@ten23.health); +41 79 489 39 05

**3i Group:** Kathryn van der Kroft, [Kathryn.VanDerKroft@3i.com](mailto:Kathryn.VanDerKroft@3i.com) ; +44 20 7975 3021